The VISTA-16 trial of varespladib, a secretory phospholipase A2 (sPLA2) 
inhibitor, in patients with an acute coronary syndrome was terminated 
prematurely owing to futility and a signal towards harm. Despite these 
discouraging results, therapies that target inflammation to modify pathways in 
atherogenesis remain an area of active investigation.